The purpose of this study was to prepare a tetravalent anti-human CD22 recombinant antibody with improved antitumor activity and a half life longer than that of its divalent counterpart. We compared the ability of tetravalent vs. divalent antibody to associate/dissociate to/from CD22-positive Daudi cells, to interact with murine and human Fcgamma receptors (FcgammaR), to bind human complement component C1q, to inhibit the growth of tumor cells, to diffuse into various tissues, to be internalized by Daudi cells, to react with human neonatal Fc receptors (FcRn), and to persist in the circulation of normal mice. As compared to the murine or chimeric divalent antibodies, the chimeric tetravalent counterpart has a longer half life in mice. It also has an affinity for FcRns that is identical to that of human IgG. The tetravalent antibody has increased antitumor activity in vitro and completely conserved effector functions (binding to FcgammaR-positive cells and to C1q) in vitro. Despite its 33% higher molecular weight, it penetrates mouse tissues as well as its divalent antibody counterpart. Based on the improved in vitro performance and pharmacokinetics of the tetravalent antibody it will now be tested for its antitumor activity in vivo.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.intimp.2005.11.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ebastine-mediated destabilization of E3 ligase MKRN1 protects against metabolic dysfunction-associated steatohepatitis.
Cell Mol Life Sci
January 2025
Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition encompassing metabolic dysfunction-associated steatotic liver (MASL) and metabolic dysfunction-associated steatohepatitis (MASH), which can progress to fibrosis, cirrhosis, or hepatocellular carcinoma (HCC). The heterogeneous and complex nature of MASLD complicates optimal drug development. Ebastine, an antihistamine, exhibits antitumor activity in various types of cancer.
View Article and Find Full Text PDFThe novel piperine derivative MHJ-LN inhibits breast cancer by inducing apoptosis via p53 activation.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, China.
Triple-negative breast cancer (TNBC) is characterized by high aggressiveness and recurrence rates due to the lack of effective treatment options. Piperine, a natural alkaloid extracted from black pepper, has demonstrated significant anticancer potential in recent years. Therefore, developing piperine derivatives to enhance its anticancer effects holds critical clinical significance.
View Article and Find Full Text PDFDesign, Synthesis and Biological Evaluation of Novel 9H Purine Derivatives as Potent CDK9 Inhibitors.
Chem Biol Drug Des
February 2025
School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
Cyclin-dependent kinase 9 (CDK9) is considered as an important target in the research of antitumor drugs. Taking the CDK2/9 inhibitor CYC065 as the positive control and an in-house library compound (64) as the lead compound, four classes of 22 target compounds with 9H purine as the core structure were designed to establish structure-activity relationships (SAR). In general, SAR of 9H purine CDK9 inhibitors is systematically described in this paper, resulting in the discovery of two compounds (B2 and B5) with further research value.
View Article and Find Full Text PDFLocation of 7-Aminoactinomycin D in Micellar Medium Depends on Ionic Nature of the Surfactant Head Group.
Luminescence
February 2025
Department of Chemistry, University of Calcutta, Kolkata, India.
7-Aminoactinomycin D (7AAMD) is the fluorescent analogue of the anticancer drug actinomycin D (AMD). In order to overcome toxic side effects and enhanced bioavailability of 7AAMD, micellar drug carrier systems could be useful. We have used cationic (hexadecetyltrimethylammonium bromide [CTAB]), anionic (sodium dodecyl sulphate [SDS]) and non-ionic (t-octylphenoxypolyoxyethanol, Triton-X100 [TX 100]) surfactants to prepare micelle.
View Article and Find Full Text PDFA Bifunctional Lysosome-Targeting Chimera Nanoplatform for Tumor-Selective Protein Degradation and Enhanced Cancer Immunotherapy.
Adv Mater
January 2025
Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
Lysosome-targeting chimeras (LYTACs) have recently emerged as a promising therapeutic strategy for degrading extracellular and membrane-associated pathogenic proteins by hijacking lysosome-targeting receptors. However, the antitumor performance of LYTAC is limited by its insufficient tumor accumulation and nonspecific activation. Additionally, the synergistic effects of LYTACs and other therapeutic modalities are crucial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!